Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 1

1327 - Alterations of cellular proliferation, apoptosis and autophagy by cucurbitacin B treatment in colon cancer cells


19 Dec 2015


Poster presentation 1


Moltira Promkan


Annals of Oncology (2015) 26 (suppl_9): 148-152. 10.1093/annonc/mdv533


M. Promkan1, S. Dakeng2, P. Suebsakwong3, A. Suksamrarn3, P. Patmasiriwat4

Author affiliations

  • 1 Clinical Microscopy, Faculty of Medical Technology, Mahidol University, 73170 - Nakhon Pathom/TH
  • 2 Clinical Microscopy, Faculty of Medical Technology, Mahidol University, 73170 - Nkhon Pathom/TH
  • 3 Faculty Of Science, Ramkhamhaeng University, Bangkok/TH
  • 4 Clinical Microscopy, Faculty of Medical Technology, Mahidol University, Nkhon Pathom/TH


Abstract 1327


Cucurbitacin B, an oxygenated tetracyclic triterpenoid extracted from the Thai medicinal plant Trichosanthes cucumerina L., exhibited strong anti-proliferative effects against breast cancer cells. However, the molecular mechanism is not completely understood, especially in colon cancer. Colon or colorectal cancer is one of the most common and the leading causes of cancer-related deaths worldwide including in Thailand.


In this study, we explore the effect of cucurbitacin B on colon cancer cells. Caco-2 and SW620 were treated with the cucurbitacin B and determined for the inhibitory effects on the cell proliferation, transwell cell migration and invasion assay and also effected on colony formation. We examine the influence of cucurbitacin B on apoptosis and autophagy in colon cancer cells.


Upon cucurbitacin B treatment, we found it obvious that cucurbitacin B inhibited cellular proliferation, migration, invasion and colony formation by using anchorage independent growth. The result of flow cytometry also showed that cucurbitacin B can induce apoptosis and autophagy.


Our findings suggest that cucurbitacin B is effectively inhibiting colon cancer, Caco-2 and SW620 cells. However, these findings are now under further investigation in other cell types and/or other mechanisms that may contribute to the development of cucurbitacin B to anti-colon cancer agents. This submitted work provides another crucial progression in the result of cucurbitacin B in colon cancer cells. It may lead to the future application of cucurbitacin B for colon cancer therapy.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings